{"disease":{"id":"dermatomyositis-adult-type","name":"dermatomyositis adult type"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05375435","title":"Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT05986162","title":"Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":44,"lead_sponsor_name":"Biotech Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04966884","title":"The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT03529955","title":"Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Tulane University","has_results":true},{"nct_id":"NCT06433999","title":"A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Priovant Therapeutics, Inc.","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}